Lundbeck

LundbeckH. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease - we call this Progress in Mind.

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. We have research centers in China, Denmark and the United States and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5 billion in 2014 (EUR 1.8 billion; USD 2.4 billion).

Lundbeck's shares are listed on the stock exchange in Copenhagen under the symbol "LUN". Lundbeck has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol "HLUYY".

www.lundbeck.com

Lundbeck RSS Channel

Display # 
Title Published Date
Kåre Schultz appointed new president and CEO of Lundbeck 06 May 2015
Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease 15 December 2013
The solid momentum continues - New Products up by 41% 06 November 2013
Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine) 01 October 2013
Vortioxetine, a new multimodal agent in development for the treatment of major depression 23 May 2013
Lundbeck is well on track to deliver on guidance for 2013 01 May 2013
Lundbeck announces positive results for Brintellix™ (vortioxetine) 08 April 2013
Lundbeck and Otsuka further expand their alliance and enter into collaboration 26 March 2013
Lundbeck on track to meet financial expectations and renew its product portfolio 08 August 2012
Lundbeck's Lu AE58054 meets primary endpoint 29 May 2012
Statistically significant clinical phase III results of Lu AA21004 14 May 2012
Lundbeck and Otsuka Pharmaceutical sign historic agreement 13 November 2011
Lundbeck's third quarter report 2011 - The positive momentum continues 10 November 2011
Lundbeck's first half report 2011 11 August 2011
Lundbeck's partner Mochida receives approval of Lexapro in Japan 23 April 2011
A new pharmaceutical candidate enters Lundbeck's development pipeline 30 March 2011
Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011 24 February 2011
The clinical phase III programme commenced on zicronapine 20 January 2011
First two clinical phase III studies confirm the profile of nalmefene 03 January 2011
Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis 16 December 2010

Most Popular Now

A new method cuts the cost of drug-…

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu...

Read more

Six leading scientists to receive p…

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo...

Read more

Pfizer announces publication of new…

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po...

Read more

Why is breast cancer common but hea…

Malignant cancers strike certain organs, such as the colon or breast, more often than others. In an Opinion publishing August 9 in Trends in Cancer, researchers propose t...

Read more

Amgen and Advaxis enter global canc…

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical inve...

Read more

Legions of nanorobots target cancer…

Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have develope...

Read more

Researchers develop safer opioid pa…

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni...

Read more

Natural compound from a deep-water …

Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains ...

Read more

Esketamine receives Breakthrough Th…

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has gran...

Read more

Intestinal flora effects drug respo…

Intestinal flora has multiple influences on human health, but researchers have revealed that it is also likely to have an effect on the body's response to drugs. Recent r...

Read more

Bayer and CRISPR Therapeutics joint…

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape...

Read more

Outdated assessment of treatment re…

Tumor shrinkage is not the only measure of a successful anti-cancer therapy. A University of Colorado Cancer Center article published in the journal Frontiers in Oncology...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016